AHA 2020 – sotagliflozin wins come too late for Lexicon

Positive data with the SGLT1/2 inhibitor sotaglifolozin in heart failure and chronic kidney disease might have come too late for its beleaguered developer, Lexicon. But signs that the project worked in heart failure patients with both reduced and preserved ejection fractions raise hopes that a similar effect might be seen with the approved SGLT2s.